Exogene Limited

TCRlcLNP - Combining long-circulating Liquid Nanoparticles with cancer-targeting T-Cell Receptors to better deliver immunotherapies in the tumour microenvironment.

SpyTCR-RBNP - A novel drug delivery system combining cancer-targeting TCRs with biocompatible red blood cell-derived nanoparticles (RBNPs) to dramatically increase the effectiveness of advanced precision medicine treatments and immunotherapies.

ST TCR - Unlocking the discovery of novel shared targets and T-cell receptors for precision cancer therapies

SpeedTCR - Unlocking the discovery of TCRs for HLA-peptide based and other cancer therapies

**Need** According to Cancer Research UK, ~367,000 new cancer cases are diagnosed every year in the UK. Cancer kills 165,000 people each year in the UK. There is the urgent need for "new curative treatments for solid tumour cancer... cheaply and effectively" (NHS-Long Term Plan). **Challenge** T-cell-receptor-based cell therapies are promising curative tr...

**TCRID - Speeding up T-Cell receptor research and target identification through AI** Traditional cancer therapies (e.g. chemotherapy, radiotherapy, surgery) are often not curative, do not prevent cancer from re-emerging and require continuous intervention. T-cell-receptor(TCR)-based cell therapies are new, promising curative treatments for otherwise untr...